The inflammatory microenvironment and microbiome in prostate cancer development

Nature Reviews. Urology
Karen S SfanosAngelo M De Marzo

Abstract

Chronic inflammation promotes the development of several types of solid cancers and might contribute to prostate carcinogenesis. This hypothesis partly originates in the frequent observation of inflammatory cells in the prostate microenvironment of adult men. Inflammation is associated with putative prostate cancer precursor lesions, termed proliferative inflammatory atrophy. Inflammation might drive prostate carcinogenesis via oxidative stress and generation of reactive oxygen species that induce mutagenesis. Additionally, inflammatory stress might cause epigenetic alterations that promote neoplastic transformation. Proliferative inflammatory atrophy is enriched for proliferative luminal epithelial cells of intermediate phenotype that might be prone to genomic alterations leading to prostatic intraepithelial neoplasia and prostate cancer. Studies in animals suggest that inflammatory changes in the prostate microenvironment contribute to reprogramming of prostate epithelial cells, a possible step in tumour initiation. Prostatic infection, concurrent with epithelial barrier disruption, might be a key driver of an inflammatory microenvironment; the discovery of a urinary microbiome indicates a potential source of frequent exposur...Continue Reading

References

Feb 1, 1976·Urology·W R FairN Wehner
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D M HockenberyS J Korsmeyer
Dec 1, 1982·British Journal of Urology·R S KirbyK E Shuttleworth
Dec 14, 1999·The American Journal of Pathology·A M De MarzoW G Nelson
Aug 12, 2000·BJU International·J Irani, J M Goujon
Jul 9, 2002·Urology·Leslie K DennisJames C Torner
Apr 15, 2003·The Prostate·David G BostwickKenneth A Iczkowski
Apr 23, 2003·The American Journal of Pathology·Geert J L H van LeendersAngelo M De Marzo
Jul 25, 2003·The New England Journal of Medicine·William G NelsonWilliam B Isaacs
Jan 9, 2004·Epidemiology·Rosebud O RobertsSteven J Jacobsen
Jan 10, 2004·The Journal of Urology·Elizabeth A Platz, Angelo M De Marzo
Oct 23, 2004·Carcinogenesis·Ganesh S PalapattuWilliam G Nelson
Mar 1, 2005·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tarja AnttilaMatti Hakama
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wanzhong WangJan-Erik Damber
May 17, 2006·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Siobhan SutcliffeElizabeth A Platz
Jul 25, 2006·Blood·Marc Beyer, Joachim L Schultze
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ashley M MillerPavel Pisa
Jan 3, 2007·Prostate Cancer and Prostatic Diseases·E V VykhovanetsS Gupta
Mar 27, 2007·Nature Reviews. Cancer·Angelo M De MarzoWilliam G Nelson
Aug 9, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Siobhan SutcliffeElizabeth A Platz
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yukiko KiniwaRong-Fu Wang
Mar 28, 2008·Immunological Reviews·Richard Kennedy, Esteban Celis
May 17, 2008·Nature Reviews. Immunology·Stephen J GalliMindy Tsai
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen Sandell SfanosCharles G Drake
Jun 24, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Bora GurelAngelo M De Marzo
Jul 29, 2008·Archivum Immunologiae Et Therapiae Experimentalis·Bozena Zdrodowska-StefanowZofia Galewska
Sep 5, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Wen-Yi HuangCharles S Rabkin
Oct 23, 2008·The Prostate·Franz Josef Marx, Axel Karenberg
Feb 10, 2009·Proceedings of the National Academy of Sciences of the United States of America·Karen S SfanosWilliam B Isaacs
Feb 28, 2009·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Wanzhong WangJan-Erik Damber
Mar 26, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Kathleen EbeltElfriede Noessner
May 15, 2009·PloS One·Kiran YanamandraLudmilla A Morozova-Roche

❮ Previous
Next ❯

Citations

Jun 2, 2018·Medicinal Research Reviews·Hui HuaYangfu Jiang
Aug 24, 2018·Current Opinion in Urology·Rafael R Tourinho-BarbosaRafael Sanchez-Salas
Jun 1, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Harsimar B KaurTamara L Lotan
Sep 30, 2018·Disease Models & Mechanisms·Clémentine Le MagnenCory Abate-Shen
Feb 6, 2018·Scientific Reports·Massimiliano RuscicaMonica Gomaraschi
Feb 5, 2019·AJR. American Journal of Roentgenology·Andreas M HötkerOguz Akin
Feb 12, 2019·Nature Reviews. Urology·Karen S Sfanos, Corinne E Joshu
Aug 8, 2018·Cold Spring Harbor Perspectives in Medicine·Levent TrabzonluAngelo M De Marzo
Apr 3, 2019·Cancers·Francesco MassariGiovanni Brandi
Aug 15, 2019·Molecular Nutrition & Food Research·Jack Coode-BateRichard F Mithen
Jan 29, 2020·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Holger Brüggemann, Munir A Al-Zeer
Feb 26, 2020·Expert Opinion on Biological Therapy·Susan F Slovin
Mar 4, 2020·Diagnostics·Sanjeev ShuklaSanjay Gupta
Feb 6, 2020·The American Journal of Gastroenterology·Muhammad B Hammami, Uma Mahadevan
May 14, 2020·International Journal of Cancer. Journal International Du Cancer·Travis J MeyersJohn S Witte
Jun 4, 2020·Current Urology Reports·Zhuo Tony SuAmin Sedaghat Herati
Jul 17, 2018·Frontiers in Microbiology·Andrzej GórskiKaren S Sfanos
Nov 28, 2018·BMC Cancer·Arunangshu GhoshalMieke Van Hemelrijck
Feb 20, 2020·Nature Reviews. Urology·Paweł ŁaniewskiMelissa M Herbst-Kralovetz
Mar 28, 2020·PLoS Pathogens·Mykhaylo UsykUNKNOWN Costa Rica HPV Vaccine Trial (CVT) Group
Jul 16, 2020·Investigative and Clinical Urology·Kwang Woo LeeYoung Ho Kim
Jun 18, 2020·Nature Reviews. Cancer·Johann S de BonoAndrea Alimonti
Sep 9, 2020·Metabolomics : Official Journal of the Metabolomic Society·Noriko NakamuraRichard D Beger
Nov 24, 2018·Nature Reviews. Urology·Pasquale Rescigno, Johann S de Bono
Nov 17, 2019·Nature Reviews. Urology·Signe AltmäeReet Mändar
Sep 5, 2020·Infectious Agents and Cancer·Paul KatongoleNixon Niyonzima
Aug 23, 2020·Journal of Clinical Medicine·Koji HatanoNorio Nonomura
May 20, 2019·Current Urology Reports·Petar BajicLarissa Bresler
Oct 9, 2019·Prostate Cancer and Prostatic Diseases·Yuqiu GeGaoxiang Ma
Oct 19, 2019·Medicine and Science in Sports and Exercise·Saber SaedmocheshiDariush Sheikholeslami-Vatani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.